BioAge Labs, Inc. Common Stock

BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. P...

BioAge Labs, a clinical-stage biotechnology company, announced it will participate in the Jefferies Global Healthcare Conference (June 3-4, 2026) and Goldman Sachs Global Healthcare Conference (June 8-10, 2026). Company executives will present and hold one-on-one meetings at both events. BioAge is developing BGE-102, an NLRP3 inhibitor for cardio...

Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron present...

BioAge Labs announced positive Phase 1 results for BGE-102, an oral NLRP3 inhibitor, showing potential best-in-class reductions in hsCRP (high-sensitivity C-reactive protein) of ≥85% at both 60 mg and 120 mg once-daily doses in participants with obesity and elevated inflammation. The drug was well tolerated across all dose levels. The company p...

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 5.9 million shares at $19.50 per share, raising approximately $115 million in gross proceeds. The company plans to use the funds for research, development, and manufacturing of its product candidates, includi...